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Abstract
We develop a Bayesian nonparametric (BNP) approach to evaluate the causal effect of treat-
ment in a randomized trial where a nonterminal event may be censored by a terminal event, but
not vice versa (i.e., semi-competing risks). Based on the idea of principal stratification, we de-
fine a novel estimand for the causal effect of treatment on the nonterminal event. We introduce
identification assumptions, indexed by a sensitivity parameter, and show how to draw inference
using our BNP approach. We conduct simulation studies and illustrate our methodology using
data from a brain cancer trial.
KEY WORDS: Bayesian nonparametrics; Brain cancer trial; Causal inference; Identification
assumptions; Principal stratification; Sensitivity analysis.
1 Introduction
Semi-competing risks (Fine and others, 2001) occur in studies where observation of a nonterminal
event (e.g., progression) may be pre-empted by a terminal event (e.g., death), but not vice versa.
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In randomized clinical trials to evaluate treatments of life-threatening diseases, patients are often
observed for specific types of disease progression and survival. Often, the primary outcome is patient
survival, resulting in data analyses focusing on the terminal event using standard survival analysis
tools (Ibrahim and others, 2005). However, there may also be interest in understanding the causal
effect of treatment on nonterminal outcomes such as progression, readmission, etc. An example
is a randomized trial for the treatment of malignant brain tumors, where one of the important
progression endpoints is based on deterioration of the cerebellum. An important feature of this
progression endpoint is that it is biologically plausible that a patient could die without cerebellar
deterioration. Thus, analyzing the effect of treatment on progression needs to account for the fact
that progression is not well-defined after death.
Varadhan and others (2014) reviews models that have been proposed for analyzing semi-
competing data. These models can be classified into two broad categories: models for the dis-
tribution of the observable data, e.g., cause-specific hazards, sub-distribution functions (Fix and
Neyman, 1951; Hougaard, 1999; Xu and others, 2010; Lee and others, 2015) and models for the
distribution of the latent failure times (Robins, 1995b,a; Lin and others, 1996; Wang, 2003; Peng
and Fine, 2007; Ding and others, 2009; Peng and Fine, 2012; Chen, 2012; Hsieh and Huang, 2012;
Comment and others, 2019). Xu and others (2010) argued against the use of latent failure time
models because the marginal distribution of the nonterminal event is hypothetical. This is because
the joint distribution of the nonterminal event (YP ) and terminal event (YD) is only identified on
a wedge of R2. Rather, they argued that “semi-competing risks data are better modeled using
an illness-death compartment model”, where “a subject can either transit directly to the terminal
event or first to the nonterminal event and then to the terminal event.” They proposed a Markov
shared frailty model for the transition rates. Lee and others (2015) proposed a Bayesian semi-
parametric extension, which focused on estimation of regression parameters, characterization of
dependence between event times and prediction of event times for specific covariate profiles. The
latent failure approaches of Fine and others (2001), Wang (2003) and Peng and Fine (2007) have
focused on estimating regression parameters and estimating dependence between nonterminal and
terminal event times using copula models. Robins (1995b,a) focused solely on estimating regression
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parameters and discusses causal interpretability. Recently, Comment and others (2019) proposed
a casual estimand similar to the one we discuss here, but uses different models (i.e., parametric
frailty models) and different causal assumptions (i.e., latent ignorability).
In this paper, we are interested in estimating the causal effect of treatment on the nontermi-
nal endpoint from a randomized trial generating semi-competing risk data. Using the potential
outcomes framework (Rubin, 1974), we propose a principal stratification estimand (Frangakis and
Rubin, 2002) to quantify the causal effect. Our estimand is a time-varying version of the survival
average causal effect (see, e.g., Zhang and Rubin (2003); Tchetgen Tchetgen (2014)), quantified on
a relative risk scale. We introduce assumptions that utilize baseline covariates to identify this esti-
mand from the distribution of the observable data and propose a Bayesian nonparametric (BNP)
approach for modeling this distribution. An important feature of BNP models is their large sup-
port, allowing us to approximate essentially arbitrary distributions (Ishwaran and James, 2001). To
handle covariates, our approach is based on the dependent Dirichlet process (DDP) prior introduced
by MacEachern (1999).
The paper is outlined as follows: Section 2 introduces the motivating brain tumor study. The
formal definition of the causal estimand is introduced in Section 3. We introduce the BNP model
in Section 4. A simulation study is summarized in Section 5. We analyze the brain tumor data in
Section 6, and conclude with brief discussion in Section 7.
2 Motivating Brain Tumor Study
The methodology is motivated by a randomized and placebo-controlled phase II trial for 222 re-
current gliomas patients, who were scheduled for tumor resection with recurrent malignant brain
tumors (Brem and others, 1995). Eligible patients had a single focus of tumor in the cerebrum, had
a Karnofsky score greater than 60, had completed radiation therapy, had not taken nitrosoureas
within 6 weeks of enrollment, and had not had systematic chemotherapy within 4 weeks of enroll-
ment. The data include 11 baseline prognostic measures and a baseline evaluation of cerebellar
function. The former includes age, race, Karnofsky performance score, local vs. whole brain radi-
ation, percent of tumor resection, previous use of nitrosoureas, and tumor histology (glioblastoma,
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anapestic astrocytoma, oligodendrolioma, or other) at implantation. Patients were randomized
to receive surgically implanted biodegradable polymer discs with or without 3.85% of carmustine.
The follow-up duration was 1 year. Of the 219 patients with complete baseline measures, 204 were
observed to die and 100 were observed to progress prior to death. Of the 15 patients who did not
die, 4 were observed to have cerebellar progression. Our goal is to estimate the causal effect of
treatment on time to cerebellar progression.
3 Causal Estimand and Identification Assumptions
3.1 Potential Outcomes and Causal Estimand
Let Y zP , Y
z
D and C
z denote progression time, death time and censoring time, under treatment
z. Here z = 0, 1 represents control and treatment group, respectively. All event times are log-
transformed. Fundamental to our setting is that Y zP 6> Y zD (i.e., progression cannot happen after
death).
The causal estimand of interest is the function
τ(u) =
Pr[Y 1P < u | Y 0D ≥ u, Y 1D ≥ u]
Pr[Y 0P < u | Y 0D ≥ u, Y 1D ≥ u]
, (1)
where τ(·) is a smooth function of u. Among patients who survive to time u under both treatments,
this estimand contrasts the risk of progression prior to time u for treatment 1 relative to treatment
0, which is a causal effect in a subgroup defined by potential outcomes. This estimand is an example
of a principal stratum causal effect (Frangakis and Rubin, 2002).
3.2 Observed Data
Let Z denote treatment assignment and X denote a vector of the baseline covariates. Let YP = Y
Z
P ,
YD = Y
Z
D and C = C
Z . Let T1 = YP ∧ YD ∧ C, δ = I(YP < YD ∧ C), T2 = YD ∧ C, and
ξ = I(YD < C) denote the observed event times and event indicators. The observed data for each
patient are O = (T1, T2, δ, ξ, Z,X). We assume that we observe n i.i.d. copies of O. Throughout,
variables subscripted by i will denote data specific to patient i.
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3.3 Identification Assumptions
We introduce the following four assumptions that are sufficient for identifying our causal estimand.
Assumption 1: Treatment is randomized, i.e.,
Z ⊥ (Y zP , Y zD, Cz,X); z = 0, 1,
and 0 < Pr[Z = 1] < 1.
This obviously holds by design in randomized trials as considered here.
Assumption 2: Censoring is non-informative in the sense that
Cz ⊥ (Y zP , Y zD) X = x; z = 0, 1,
and Pr[Cz > Y zP , C
z > Y zD|X = x] > 0 for all x.
Let λzx and G
z
x denote the conditional hazard function and conditional distribution function
of Y zD given X = x, respectively. Under Assumptions 1 and 2, λ
z
x and G
z
x are identified via the
following formulae:
λzx(t) = lim
dt→0
{
Pr[t ≤ T2 < t+ dt, ξ = 1 T2 ≥ t,X = x, Z = z]
dt
}
and
Gzx(t) = 1− exp
{
−
∫ t
0
λzx(s)ds
}
. (2)
Furthermore, the conditional sub-distribution function of Y zP given Y
z
D and X = x, V
z
x , is identified
via the following formula:
V zx (s|t) = Pr[T1 ≤ s, δ = 1 T2 = t, ξ = 1,X = x, Z = z], (3)
where s ≤ t. Together Gzx(t) and V zx (s|t) identify the joint subdistribution V zx (s, t) for (Y zP , Y zD)
given X = x.
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Assumption 3: The conditional joint distribution function of (Y 0D, Y
1
D) given X = x, Gx, follows
a Gaussian copula model, i.e.,
Gx(v, w; ρ) = Φ2,ρ[Φ
−1{G0x(v)},Φ−1{G1x(w)}], (4)
where Φ is a standard normal c.d.f. and Φ2,ρ is a bivariate normal c.d.f. with mean 0, marginal
variances 1, and correlation ρ. For fixed ρ, Gx is identified since G
0
x and G
1
x are identified. Similar
assumptions have been used in the causal mediation literature (Daniels and others, 2012).
Assumption 4: Progression time under treatment z is conditionally independent of death time
under treatment 1− z given death time under treatment z and covariates X = x, i.e.,
Y zP ⊥ Y 1−zD Y zD,X = x; z = 0, 1.
Under Assumptions 1-4, τ(·) is identified from the distribution of the observed data as follows:
τ(u) =
∫
x
∫
s<u
∫
v≥u
∫
t≥u dV
1
x (s|t)dGx(v, t)dK(x)∫
x
∫
s<u
∫
v≥u
∫
t≥u dV
0
x (s|t)dGx(v, t)dK(x)
, (5)
where K(x) is the empirical distribution of X.
4 Bayesian Regression Model
In this section, we propose a Bayesian nonparametric survival regression model on the unknown
conditional (on X = x) distribution of (Y zP , Y
z
D). However, any alternative Bayesian survival
regression models could be implemented (Hanson and Johnson, 2002; Gelfand and Kottas, 2003;
Zhou and Hanson, 2018; Sparapani and others, 2016); however the first three are restrictive in how
covariates are entered and the fourth one is semi-parametric.
4.1 Dependent Dirichlet Process - Gaussian Process Prior
We start with a review of the Dirichlet process as a prior for an unknown distribution and step by
step extend it to the Dependent Dirichlet Process - Gaussian Process prior.
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The Dirichlet process (DP) prior has been widely used as a prior model for a random unknown
probability distribution. We write H ∼ DP(α,H0) if a random distribution H of a J-dimensional
random vector V follows a DP prior, where α is known as the total mass parameter and H0 is
known as the base measure. Sethuraman (1994) provides a constructive definition of a DP, where
dH(v) =
∑∞
h=1whδθh(v), wh = νh
∏
l<h(1 − νl), θh = {θh1, . . . , θhJ} i.i.d.∼ H0 and νh i.i.d.∼ Be(1, α).
In many applications, the discrete nature of H is not appropriate. A DP mixture model extends the
DP model by replacing each point mass δθh(·) with a continuous kernel. For example, a DP mixture
of normals takes the form: dH(v) =
∑
hwhφ (v;θh,Σ) dv, where φ(·;µ,S) is the density function
of a multivariate normal random vector with mean vector µ and variance-covariance matrix S.
To introduce a prior on the conditional (on covariates X = x) distribution (Hx) of V , the DP
mixture model has been extended to a dependent DP (DDP) by replacing θh in each term with
θh(x) = {θh1(x), . . . , θhJ(x)}, which is a multivariate stochastic process indexed by x. A DDP
mixture of normals takes the form:
dHx(v) =
∑
h
whφ (v;θh(x),Σ) dv. (6)
To complete the prior specification, we need to posit a stochastic process prior for {θh(x) :
x}. A common specification are independent Gaussian process (GP) priors (MacEachern, 1999)
on {θhj(x) : x}. A GP prior is specified such that for all L ≥ 1 and (x1, . . . ,xL), the dis-
tribution of (θhj(x1), . . . , θhj(xL)) follows a multivariate normal distribution with mean vector
(µhj(x1), . . . , µhj(xL)) and (L×L) covariance matrix where the (l, l′) entry is Rj(xl,xl′). We write
{θhj(x) : x} ∼ GP(µhj(·), Rj(·, ·)). For an extensive review of the GP priors, see Rasmussen and
Williams (2006) and MacKay (1999). We model the mean function µhj(·) as a linear regression on
covariates µhj(xl;βhj) = xlβhj , with covariance process specified as
Rj(xl,xl′) = exp
{
−
D∑
d=1
(xld − xl′d)2
}
+ δll′
2, (7)
where D is the dimension of the covariate vector, δll′ = I(l = l
′) and  is a small constant (e.g.,
 = 0.1) used to ensure that the covariance function is positive definite. To ensure a reason-
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able covariance structure, continuous covariates should be standardized to have mean 0 and vari-
ance 1. More flexible covariance functions can be considered if desired. Additional priors are
introduced on the βj ’s and Σ, the details of which are discussed in Appendix A1. We write
{Hx} ∼ DDP-GP(α,Σ,GP(µj(·), Rj(·, ·)), j = 1, . . . , J).
4.2 Application to Semi-competing Risks Data
Separately for each treatment group z, we posit independent DDP-GP’s on the unknown conditional
(on X = x) probability measure (Hzx) of (Y
z
P , Y
z
D). Since V
z
x (s|t) = Hzx(Y zP ≤ s, Y zP ≤ Y zD|Y zD = t)
(s ≤ t) and Gzx(t) = Hzx(Y zD ≤ t), the prior on Hzx induces priors on V zx (s|t) and Gzx(t) (identified
under Assumptions 1 and 2) and together with the Gaussian copula for Gx implies a prior on the
estimand τ(·). The prior on Hzx also induces priors on non-identified quantities which have no
impact on our analysis. More specifics about our prior are presented in Appendix A1.
Before transitioning to the posterior sampling algorithm, note that the relevant portion of the
observed data likelihood for individual i, with data Oi = (T1i, T2i, δi, ξi, Zi,Xi) is
L(Oi) =
{
dV ZiXi(T1i|T2i)dG
Zi
Xi
(T2i)
}δiξi {∫
t>T2i
dV ZiXi(T1i|t)dG
Zi
Xi
(t)
}δi(1−ξi)
×
{(
1− V ZiXi(T2i|T2i)
)
dGZiXi(T2i)
}(1−δi)ξi {∫
t>T2i
(
1− V ZiXi(T2i|t)
)
dGZiXi(t)
}(1−δi)(1−ξi)
=
{
dHZiXi(T1i, T2i)
}δiξi {∫
t>T2i
dHZiXi(T1i, t)
}δi(1−ξi){∫
s>T1i
dHZiXi(s, T2i)
}(1−δi)ξi
×{∫
t>T2i
∫
s>T2i
dHZiXi(s, t)
}(1−δi)(1−ξi)
.
We include the second equality because it allows us to see that, using data augmentation to replace
the integrals, the joint full data likelihood is
∏n
i=1 dH
Zi
Xi
(YPi, YDi). This will allow us to use existing
posterior simulation techniques for DDP-GP models.
4.3 Posterior Simulation
The details of the MCMC algorithm are presented in Appendix A2. Here we focus on individuals
assigned to treatment z and suppress the dependence of the notation on z. As noted above, the
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MCMC implementation is based on the full data likelihood. While dHXi is an infinite mixture of
normals, we approximate it by a finite mixture with K <∞ components. This finite mixture model
for (YPi, YDi) can be replaced by a hierarchical model where (1) γi is a latent variable that selects
mixture component h (h = 1, . . . ,K) with probability wh (properly normalized to handle the finite
number of mixture components) and (2) given γi, the pair (YPi, YDi) follows a multivariate normal
distribution with mean θγi(Xi) and variance Σ.
Posterior simulation is based on this hierarchical model characterization. Importantly, all of the
full conditionals in the MCMC algorithm have a closed form representation. Details of the Markov
chain Monte Carlo posterior simulation can be found in Appendix A2.
5 Simulation Studies
5.1 Simulation Setup
We considered three simulation scenarios to evaluate the performance of our proposed approach
with 500 repeated simulations for each scenario. We generated Z ∼ Bern(0.5). Independently of
Z, we generated two independent covariates X1 and X2, where X1 followed a truncated normal
distribution with mean 4.5, variance 1 and truncation interval (2, 7.5) and X2 ∼ Bern(0.4). For
the first two simulation scenarios, we simulated progression time and death time on the log scale
as follows:
Y zP = 1.5z + 0.6X1 + 2X2 + ,
Y zD = 4z + 0.3X1 +X2 + ν.
In Scenario 1, we assumed (, ν) followed a bivariate normal distribution with mean (0, 1.5)′,
marginal variances S11 = S22 = 1, and correlation S12 = 0.75. In Scenario 2, we assumed (, ν)
to be a scaled multivariate t distribution with degree of freedom ν = 3, mean (0, 1.5)′, marginal
variance S11 = S22 = 1, and correlation S12 = 0.75. Scenario 3 explored performance under
a nonlinear covariate effect specification on progression and death times. We generated Y zP =
1.5z + 0.6Xi + 2X2 +  and Y
z
D = 4z + 0.3X1 + X2 + 0.5
√
X1 + ν, with (, ν) following the same
9
distribution as in Scenario 1.
In all scenarios, the censoring time Cz on the log scale was generated independently according
to a Unif(8, 10) distribution. For the joint distribution of Y 0D and Y
1
D in (4), we set ρ = ρ
o = 0.5 in
the Gaussian copula as the truth. We generated (Zi, X1i, X2i, YPi, YDi, Ci) for n = 500 independent
patients and then coarsened to (Zi, X1i, X2i, Ti1, Ti2, δi, ξi).
To explore sensitivity of τ(u) with respect to ρ, we conducted inference for τ(u) under several
values of ρ = 0.2, 0.5, 0.8. For all three scenarios, we specified hyperparameters as described in
Appendix A1.
For comparative purposes, we implemented a naive Bayesian (Naive) model by assuming that
the conditional probability measure (Hzx) of (Y
z
P , Y
z
D) follows a multivariate normal distribution
with mean (x′βzP ,x
′βzD) and variance-covariance matrix S
z, with conjugate multivariate normal
priors on βzP and β
z
D and an inverse Wishart prior on S
z (i.e., βzP ∼ MN(0, τ2P I), βzP ∼ MN(0, τ2DI),
and Sz ∼ Inverse Wishart(ν,Ψ), z = 0, 1).
For each analysis, we ran 5,000 MCMC iterations with an initial burn-in of 2,000 iterations and
a thinning factor of 10. The convergence diagnostics using the R package coda show no evidence
of practical convergence problems.
5.2 Simulation Results
We first report on the performance in terms of recovering the true treatment-specific marginal
survival functions for time to death. For the BNP approach, Figure 1 shows, for each of the
three simulation scenarios and by treatment group (first and second rows refer to treatments 0
and 1, respectively), the true survival functions (solid line), the posterior mean survival functions
averaged over simulated datasets (dashed line), and 95% point-wise credible intervals (computed
using quantiles) averaged over simulated datasets (dotted lines) on the original time scale (days).
As another metric of performance, we computed, for each simulated dataset, the root mean squared
error (RMSE) taken as the square root of the average of the squared errors at 34 equally-spaced
grid points in log-scaled time interval (0, 10). For each scenario, Table 1 summarizes the mean
and standard deviation of RMSE across the 500 simulated datasets. Both Figure 1 and Table 1
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show that our proposed BNP procedure performs well, for each of the three scenarios, in terms of
recovering the true survival function.
Table 1 also shows the mean and standard deviation of RMSE for the Naive model. In scenario 1,
the model matches the simulation true model, thereby yielding comparable results as the proposed
BNP model. In contrast, the Naive model performs worse than the BNP model in scenario 2 when
the fitted model does not match the simulation truth. In scenario 3, the BNP model performs
slightly better than the Naive model. Overall, the proposed BNP model is more robust compared
to the Naive model.
Evaluation of τ(·) requires evaluation of Gzx as the second marginal under Hzx. Expression (5)
allows us now to estimate τ(u). Both the numerator and denominator can be evaluated as func-
tionals of the currently imputed random probability measure Hzx(Y
z
P , Y
z
D) of time to log progression
Y zP and time to log death Y
z
D under treatment z, marginalizing with respect to the empirical distri-
bution of x. Each iteration of the posterior MCMC simulation evaluates a point-wise estimate and
we estimate the posterior mean of τ(u) as τˆ(u) = Mean {τ(u) | data} across iterations. We also
report the mean RMSE in estimating the τˆ(u) by averaging over 500 repeated simulations under
the proposed BNP model and the Naive model. Table 2 summarizes the results.
Figure 2 shows τˆ(u) versus u in the three scenarios, respectively, using ρ = 0.2, 0.5 and 0.8. As
shown in Figure 2, in all three scenarios, when ρ = ρo = 0.5, the estimates under the proposed
BNP model reliably recover the simulated true τ(u) and avoid the excessive bias seen with other
ρ values. This agrees with the results reported in Table 2 that ρ = 0.5 always yields the smallest
mean RMSE in all three scenarios. Furthermore, when ρ = 0.5, the proposed BNP model has
smaller mean RMSE compared to the Naive model. When ρ = 0.2 or 0.8, the BNP model performs
better or comparable to the Naive model in terms of providing smaller mean RMSE and variability
of RMSE across simulations.
6 Brain Tumor Data Analysis
An initial analysis of the brain tumor death outcome using Kaplan-Meier is given in Figure 3,
indicating that the treatment group has higher estimated survival probabilities. The estimated
11
difference at 365 days is 2.6% (95% CI: -8.1% to 13.3%). Figure 3 plots the estimated posterior
survival curves for treatment and control groups marginalized over the distribution of covariate with
95% credible intervals; panels (a) and (b) display the results for the BNP and Naive approaches,
respectively. Using the BNP approach, the estimated posterior difference in survival at 365 days
is 6.2% (95% CI: -1.2% to 13.3%). For the Naive approach, the estimated posterior difference in
survival at 365 days is 8.4% (95% CI: 0.2% to 17.9%). The BNP approach produces comparable
or higher treatment-specific estimates of survival and greater treatment differences than Kaplan-
Meier. In contrast, the Naive approach produces comparable or lower (higher) estimate of survival
for the control (treatment) group than Kaplan-Meier. Comparatively speaking, the Naive approach
produces lower treatment-specific posterior estimates of survival than the BNP approach. When we
compare the fit to the observed survival data of the BNP and Naive approaches using the log-pseudo
marginal likelihood (LPML) (Geisser and Eddy, 1979), a leave-one-out cross-validation statistic,
we see the BNP performs better. Specifically, the LPML for the treatment arm is -144 and -161
for the BNP and Naive approaches, respectively. The corresponding numbers for the control arm
are -137 and -174.
For the BNP (see panel (a)) and Naive (see panel (b)) approaches, Figure 4 plots the posterior
estimates (along with point-wise 95% credible intervals) of the causal estimand τ(u) versus u for
three choices of ρ, 0.2, 0.5 and 0.8. Except near u = 0, there are no appreciable differences between
the two approaches. In addition, the results are insensitive to choice of ρ. Overall, this analysis
shows that there is a lower estimated risk of progression for treatment versus of control at all
time points, except near zero. However, there is appreciable uncertainty, characterized by wide
posterior credible intervals, that precludes more definitive conclusions about the difference between
treatment groups with regards to progression. When we compare the fit to the observed survival
and progression data of the BNP and Naive approaches using LPML, we see that the approaches
perform comparably. Specifically, the LPML for the treatment arm is -227 and -232 for the BNP
and Naive approaches, respectively. The corresponding numbers for the control arm are -215 and
-214.
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7 Discussion
In this paper, we proposed a causal estimand for characterizing the effect of treatment on progres-
sion in a randomized trials with a semi-competing risks data structure. We introduced a set of
identification assumptions, indexed by a non-identifiable sensitivity parameter that quantifies the
correlation between survival under treatment and survival under control. Selecting a range of the
sensitivity parameter ρ in a specific trial will depend on clinical considerations. For example, in
trial of a biomarker targeted therapy, one might expect weaker correlation, since survival under
control might be primarily determined by co-morbidities and the survival under treatment might
be more determined by the presence of the targeted molecular aberration. In contrast, for some
chemotherapies, the same factors that impact survival under control may equally impact survival
under treatment, e.g., co-morbidities, social support, etc. Fortunately, the sensitivity parameter is
bounded between -1 and 1 and, in most settings, should be positive; a range should be selected in
close collaboration with subject matter experts.
We proposed a flexible Bayesian nonparametric approach for modeling the distribution of the
observed data. Since the causal estimand is a functional of the distribution of the observed data
and ρ, we draw inference about it using posterior summarization. Our procedure can easily be
extended to accommodate a prior distribution on ρ, which will allow for integrated inference. Our
procedure also allows for posterior inferences about other identified causal contrasts such as the
distribution of survival under treatment versus under control. The procedure can also be used for
predictive inference for patients with specific covariate profiles.
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Appendix
A1: Determining Prior Hyperparameters
As priors for βzhj in the GP mean function, we assume β
z
hj ∼ N(βz0j ,Λz0j). We assume Λz0j ∼
Inverse-Wishart(λz0,Ψ
z), where E[Λz0j ] =
Ψz
λz0−3 . The precision parameter α in the DDP is assumed
to be distributed Ga(λ1, λ2).
In applications of Bayesian inference with small to moderate sample sizes, a critical step is to
fix values for all hyperparameters ω = {βz0j ,Σz0j , λz0,Φz, z = 0, 1, j = 0, 1, λ1, λ2}. Inappropriate
information could be introduced by improper numerical values, leading to inaccurate posterior
inference. We use an empirical Bayes method to obtain βz0 = (β
z
01,β
z
02) by fitting a bivariate
normal distribution for responses of patients under treatment z, Y | Z = z ∼ N(xβz0 ,Σβ0). For
Σz0j , we assume a diagonal matrix with the diagonal values being 10. After an empirical estimate
of Σˆz is computed, we tune λz0 and Φ
z so that the prior mean of Σz matches the empirical estimate,
λz0 = 4 and Φ
z = Σˆz. Finally, we assume λ1 = λ2 = 1.
A2: MCMC Computational Details
Unless required for clarity, we suppress dependence of the notation on treatment z. Here j is used
to denote endpoint (j = 1 for progression and j = 2 for death). We define
Σ =
 σ21 σ12
σ21 σ
2
2
 .
Let Ah = {i : γi = h} and nh = |Ah|, Yi = (YPi, YDi), θ?hj = (θhj(X1), . . . , θhj(Xn)) (h = 1, . . . ,K),
X is an n ×D matrix where the ith row contains the D-dimensional covariate vector Xi for the
i-th patient, Rj is an n × n matrix where the (i, i′) entry is Rj(Xi,Xi′), Uh is an nh × n matrix
where the kth row refers to the kth patient in Ah, the ith column refers to patient i and (k, i)
element is the indicator that the patient in kth row is the same as the patient in the ith column,
In is an n × n identity matrix, Y˜hj = {Y˜ji : γi = h} where Y˜1i = YPi − σ12σ22 (YDi − θγi2(Xi)) and
Y˜2i = YDi − σ21σ21 (YPi − θγi1(Xi)), σ˜
2
1 = σ
2
1 − σ12σ21σ22 and σ˜
2
2 = σ
2
2 − σ12σ21σ21 .
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For z = 0, 1, we iterate through the following 6 updating steps:
1. Update wh
vh ∼ Beta(1 + nh, α+
∑
j>h
nj),
where nh =
∑nk
i=1 I(γi = h) is the number of observations such that γi = h. Then w1 = v1
and wh = vh
∏
j<h(1− vj).
2. Update α
Assuming that α ∼ Ga(λ1, λ2),
α ∼ Ga(λ1 +H − 1, λ2 −
H−1∑
h=1
log(1− vh)),
where vh is generated from step 1.
3. Update Σ
Σ | · ∼ Inverse Wishart
λ0 + n,Ψ + K∑
h=1
∑
i:γi=h
(Yi − θh(Xi))(Yi − θh(Xi))′

4. Update θ?hj , j = 1, 2
p(θ?hj | ·) ∝ p(θ?hj)
∏
i:γi=h
p(Yi | θh(Xi))
∝ exp
{
−1
2
(θ?hj −Xβhj)′R−1j (θ?hj −Xβhj)
}
× exp
−12 ∑
i:γi=h
(Yi − θh(Xi))′Σ−1(Yi − θh(Xi))

∼ N
{R−1j + U ′hUhσ˜2j In
}−1{
U ′h
Y˜hj
σ˜2j
+R−1j Xβhj
}
,
{
R−1j +
U ′hUh
σ˜2j
In
}−1
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5. Update βhj
p(βhj | ·) ∝ p(βhj) exp
{
−1
2
(θ?hj −Xβhj)′R−1j (θ?hj −Xβhj)
}
∼ N(Λhj
(
X ′R−1j θ
?
hj + Λ
−1
0j β0j
)
,Λhj),
where Λhj = (X
′R−1j X + Λ
−1
0j )
−1.
6. Update (γi,Yi), where Yi = (YPi, YDi).
We write p(γi,Yi | ·) as p(Yi | γi, ·)p(γi | ·) where · includes Oi.
• If δi = ξi = 1
Pr(γi = h | ·) ∝ whφ(T1,i, T2,i;θh(Xi),Σ);
p(Yi | γi, ·) is point mass at Yi = (T1i, T2i).
• If δi = ξi = 0 (i.e., YPi > T2i, YDi > T2i),
Pr(γi = h | ·) ∝
∫
t>T2i
∫
s>T2i
whφ(s, t;θh(Xi),Σ)dsdt.
p(Yi | γi, ·) = φ(Yi;θγi(Xi),Σ)∫
t>T2i
∫
s>T2i
φ(s, t;θγi(Xi),Σ)dsdt
,
where YPi > T2i, YDi > T2i.
• If δi = 1 and ξi = 0
Pr(γi = h | ·) ∝
∫
t>T2i
whφ(T1i, t;θh(Xi),Σ)dt;
p(Yi | γi, ·) = φ(Yi;θγi(Xi),Σ)∫
t>T2i
φ(T1i, t;θγi(Xi),Σ)dt
,
where YPi = T1i, YDi > T2i.
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• If δi = 0 and ξi = 1
Pr(γi = h | ·) ∝
∫
s>T1i
whφ(s, T2i;θh(Xi),Σ)ds;
p(Yi | γi, ·) = φ(Yi;θγi(Xi),Σ)∫
s>T1i
φ(s, T2i;θγi(Xi),Σ)ds
,
where YPi > T1i, YDi = T2i.
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Figure 1: For each simulation scenario and by treatment group (first and second rows refer to
treatments 0 and 1, respectively), the true survival functions (solid line), the posterior mean survival
functions averaged over simulated datasets (dashed line), and 95% point-wise credible intervals
(computed using quantiles) averaged over simulated datasets (dotted lines). Survival times are on
the original scale (days).
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Figure 2: The posterior estimates of τ(u) versus u on the original scale (days) for the three scenarios
using ρ = 0.2, 0.5, 0.8, respectively. The black lines represent the simulation truth using ρo = 0.5.
The dashed lines represent 95% point-wise credible intervals (computed using quantiles) averaged
over simulated datasets.
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Figure 3: The dashed lines in (a) represent the estimated posterior mean survival curves for the
proposed BNP method. The dotdash lines in (b) represent the estimated posterior mean survival
curves for the Naive method. In both figures, the solid lines represent the Kaplan-Meier curves
of the observed survival data in control and treatment groups, and the dotted lines represent 95%
point-wise credible intervals of the posterior estimated survival curves. Survival times are on the
original scale (days).
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Figure 4: Posterior estimated τ(u) versus u on the original scale (days) in brain tumor data analysis
for different ρ’s under the proposed BNP method and the Naive method, respectively. The solid
lines represent the posterior estimated τ(u), and the dashed lines represent 95% point-wise credible
intervals.
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Scenario
Z = 0 Z = 1
BNP Naive BNP Naive
1 0.012 (0.007) 0.013 (0.007) 0.012 (0.006) 0.013 (0.007)
2 0.042 (0.022) 0.088 (0.032) 0.019 (0.007) 0.073 (0.035)
3 0.012 (0.006) 0.013 (0.007) 0.012 (0.007) 0.014 (0.007)
Table 1: For each scenario, mean and standard deviation of RMSE across 500 simulated datasets
under the proposed BNP method and the naive Bayesian method (Naive).
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Scenario
ρ = 0.2 ρ = 0.5 ρ = 0.8
BNP Naive BNP Naive BNP Naive
1 0.286 (0.087) 0.328 (0.126) 0.059 (0.035) 0.073 (0.051) 0.185 (0.037) 0.207 (0.047)
2 0.277 (0.128) 0.493 (0.250) 0.090 (0.062) 0.199 (0.169) 0.261 (0.070) 0.243 (0.111)
3 0.106 (0.032) 0.105 (0.038) 0.033 (0.016) 0.035 (0.021) 0.086 (0.028) 0.097 (0.034)
Table 2: Means and standard deviations of RMSE for estimating τˆ(u) across 500 simulations in
three scenarios under the proposed BNP approach and naive Bayesian method (Naive), respectively.
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